Korean drugmakers challenge Glivec in generics fight
Published: 2013-05-29 07:00:00
Updated: 2013-05-29 07:00:00
Korean pharmaceutical firms are gearing up to enter the 100 billion won leukemia drug market as the main patent of the market leader, Novartis’s Glivec (imatinib), is to expire on June 3, allowing for generic versions of the “miracle cancer drug.”
According to the Ministry of Food and Drug Sa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
